Swissmedic

Summary report on authorisation - Enhertu®

Marketing authorisation granted for Enhertu® (trastuzumab deruxtecan), a human medicinal product.

Low obligation Product class Pharmaceuticals Switzerland Pharmaceuticals

23.06.2026

Dates and deadlines

Applies from

2026-06-23

Read the official source ↗

Published by Swissmedic. HealthSignal links to the original document; the summary above is extracted from the source text.